Literature DB >> 25877910

Quality indicators in rheumatoid arthritis: results from the METEOR database.

Victoria Navarro-Compán1, Josef S Smolen2, Tom W J Huizinga3, Robert Landewé4, Gianfranco Ferraccioli5, José A P da Silva6, Robert J Moots7, Jonathan Kay8, Désirée van der Heijde3.   

Abstract

OBJECTIVE: To test the feasibility of collecting, storing, retrieving and analysing necessary information to fulfil a preliminary set of quality indicators (QIs) that have been proposed by an international task force in a large multinational clinical practice database of patients with RA.
METHODS: Data from all 12 487 patients with 46 005 visits in the Measurement of Efficacy of Treatment in the Era of Outcome in Rheumatology database from January 2008 until January 2012 were analysed to test the feasibility of collecting information on 10 QIs: time to diagnosis; frequency of visits; assessment of autoantibodies and radiographs, disease activity and function; disease remission, low disease activity, normal function; time to first DMARD and type of first DMARD. For each QI, two aspects were assessed: information availability and target achievement.
RESULTS: Information was available for <50% of patients regarding the following QIs: time to diagnosis, assessment of ACPAs or radiographs, time to first DMARD and type of first DMARD. Information was available for function assessment in 49% of visits and 67% of patients and for disease activity assessment in 85% of visits and 86% of patients. Information relevant to the QI frequency of visits was available for all patients. Relevant information to calculate the proportion of patients who achieved a defined target could be obtained for all QIs.
CONCLUSION: Collecting storing, retrieving and analysing the core data necessary to meaningfully assess quality of care is feasible in a multinational, practice-based electronic database.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  care; quality indicator; rheumatoid arthritis

Mesh:

Substances:

Year:  2015        PMID: 25877910     DOI: 10.1093/rheumatology/kev108

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  11 in total

1.  [International quality indicators in rheumatology. Suggestions for rheumatoid arthritis].

Authors:  J Braun; F Bessler; H-J Lakomek; M Rudwaleit
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

Review 2.  Leveraging the electronic health record to improve quality and safety in rheumatology.

Authors:  Gabriela Schmajuk; Jinoos Yazdany
Journal:  Rheumatol Int       Date:  2017-08-29       Impact factor: 2.631

3.  [Cornerstones of quality assurance in medicine in Germany. Important impulse for the situation in treatment of rheumatism].

Authors:  J Braun; M Schneider; H-J Lakomek
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

4.  Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis.

Authors:  Chen Yu; Shangyi Jin; Yanhong Wang; Nan Jiang; Chanyuan Wu; Qian Wang; Xinping Tian; Mengtao Li; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2018-10-19       Impact factor: 2.980

5.  Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.

Authors:  Edward C Keystone; Peter C Taylor; Yoshiya Tanaka; Carol Gaich; Amy M DeLozier; Anna Dudek; Jorge Velasco Zamora; Jose Arturo Covarrubias Cobos; Terence Rooney; Stephanie de Bono; Vipin Arora; Bruno Linetzky; Michael E Weinblatt
Journal:  Ann Rheum Dis       Date:  2017-08-10       Impact factor: 19.103

6.  Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).

Authors:  Josef S Smolen; Joel M Kremer; Carol L Gaich; Amy M DeLozier; Douglas E Schlichting; Li Xie; Ivaylo Stoykov; Terence Rooney; Paul Bird; Juan Miguel Sánchez Bursón; Mark C Genovese; Bernard Combe
Journal:  Ann Rheum Dis       Date:  2016-10-31       Impact factor: 19.103

7.  Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis.

Authors:  Uta Kiltz; Robert B M Landewé; Désirée van der Heijde; Martin Rudwaleit; Michael H Weisman; Nurullah Akkoc; Annelies Boonen; Jan Brandt; Philippe Carron; Maxime Dougados; Laure Gossec; Merryn Jongkees; Pedro M Machado; Helena Marzo-Ortega; Anna Molto; Victoria Navarro-Compán; Karin Niederman; Percival Degrava Sampaio-Barros; Gleb Slobodin; Filip E Van den Bosch; Astrid van Tubergen; Salima van Weely; Dieter Wiek; Juergen Braun
Journal:  Ann Rheum Dis       Date:  2019-10-11       Impact factor: 19.103

Review 8.  The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus.

Authors:  Eun-Jung Park; Hyungjin Kim; Seung Min Jung; Yoon-Kyoung Sung; Han Joo Baek; Jisoo Lee
Journal:  Korean J Intern Med       Date:  2020-01-02       Impact factor: 2.884

9.  Clinical Outcomes of Patients with Rheumatoid Arthritis Treated in a Disease Management Program: Real-World Results.

Authors:  Pedro Santos-Moreno; Paola Castillo; Laura Villareal; Carlos Pineda; Hugo Sandoval; Omaira Valencia
Journal:  Open Access Rheumatol       Date:  2020-11-06

10.  A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference.

Authors:  Harald J Hamre; Van N Pham; Christian Kern; Rolf Rau; Jörn Klasen; Ute Schendel; Lars Gerlach; Attyla Drabik; Ludger Simon
Journal:  Patient Prefer Adherence       Date:  2018-03-16       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.